RE:RE:RE:Strategic alternatives Fair point, but with the Brexit vote being of potentially material impact to Concordia in the longer term, once their natural hedging wears off, I can appreciate that the strategic review may still take at least a few more weeks to reach its conclusion. If it does drag into 2017, that certainly would seem to be troubling, though I suppose with the US election, and the corresponding uncertainty related to drug pricing, one even could argue that late 2016 or early 2017 might still be an appropriate timeframe to conclude the strategic review. I'm sure we'll hear something of an update come the Q2 earnings' press release and conference call, and personally I'm comfortable not hearing anything more between now and then. It's been a rough past few weeks and months for those long CXR, but unfortunately that can be the nature of the game. Just as Concordia hedged some on their bets across the pond, it's prudent for us investors to do the same! GLTA